These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 33443847)
1. Comparison of Immunohistochemistry and DNA Sequencing for BRAF V600E Mutation Detection in Mandibular Ameloblastomas. da Silva Marcelino BMR; Parise GK; do Canto AM; Sassi LM; Sarmento DJS; Costa ALF; Hasséus B; Kjeller G; Schussel JL; Braz-Silva PH Appl Immunohistochem Mol Morphol; 2021 May-Jun 01; 29(5):390-393. PubMed ID: 33443847 [TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas. do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709 [TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. Mendez LD; Wolsefer NS; Asa SL; Wasman J; Yoest JM; Stojanov IJ Mod Pathol; 2022 Nov; 35(11):1570-1577. PubMed ID: 35676332 [TBL] [Abstract][Full Text] [Related]
4. Factors affecting the accuracy of anti-BRAF V600E immunohistochemistry results in ameloblastomas. Chang JYF; Lu PH; Tseng CH; Wang YP; Lee JJ; Chiang CP J Oral Pathol Med; 2023 Apr; 52(4):342-350. PubMed ID: 36625499 [TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical and genetic study of BRAF Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Ida CM; Vrana JA; Rodriguez FJ; Jentoft ME; Caron AA; Jenkins SM; Giannini C Acta Neuropathol Commun; 2013 May; 1():20. PubMed ID: 24252190 [TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature. Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650 [TBL] [Abstract][Full Text] [Related]
8. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital. Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720 [TBL] [Abstract][Full Text] [Related]
9. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas. Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205 [TBL] [Abstract][Full Text] [Related]
10. Discrepancy between immunohistochemistry and sequencing for BRAF V600E in odontogenic tumours: Comparative analysis of two VE1 antibodies. Oh KY; Cho SD; Yoon HJ; Lee JI; Hong SD J Oral Pathol Med; 2021 Jan; 50(1):85-91. PubMed ID: 32939809 [TBL] [Abstract][Full Text] [Related]
11. BRAF V600E mutation-specific immunohistochemical analysis in ameloblastomas: a 44-patient cohort study from a single institution. Owosho AA; Ladeji AM; Adebiyi KE; Olajide MA; Okoye ISI; Kehinde T; Nwizu NN; Summersgill KF Eur Arch Otorhinolaryngol; 2021 Aug; 278(8):3065-3071. PubMed ID: 33231757 [TBL] [Abstract][Full Text] [Related]
12. Detection and evaluation of the presence of the BRAF V600E mutation in ameloblastomas in an Indian population. Goes CF; Spadigam A; Dhupar A; Carvalho KM; Cota J; Syed S Indian J Pathol Microbiol; 2023; 66(2):246-251. PubMed ID: 37077063 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction. Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays. Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277 [TBL] [Abstract][Full Text] [Related]
16. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma. Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044 [TBL] [Abstract][Full Text] [Related]
17. VE1 immunohistochemistry is an adjunct tool for detection of BRAF Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405 [TBL] [Abstract][Full Text] [Related]
18. Association of MDM2 Overexpression in Ameloblastomas with Tosios KI; Kalogirou EM; Koutlas IG Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916 [TBL] [Abstract][Full Text] [Related]
19. It was not possible to detect BRAF V600E mutation in circulating cell-free DNA from patients with ameloblastoma: A diagnostic accuracy study. Martins-de-Barros AV; da Costa Araújo FA; Barros AMI; Dos Santos EGF; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; Neves RFSN; de Hollanda Valente RO; de Oliveira E Silva ED; de Vasconcelos Carvalho M J Oral Pathol Med; 2024 Apr; 53(4):258-265. PubMed ID: 38494749 [TBL] [Abstract][Full Text] [Related]
20. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma. Bullock M; O'Neill C; Chou A; Clarkson A; Dodds T; Toon C; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Learoyd DL; Capper D; von Deimling A; Clifton-Bligh RJ; Gill AJ Endocr Relat Cancer; 2012 Dec; 19(6):779-84. PubMed ID: 22997209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]